AI Summary & Key Takeaways
AI InsightConclusion: MPV can be used as a predictor of early response to the first line treatment in newly diagnosed adult primary ITP patients.
📌 3 Key Takeaways
Abstract
Background/aim: Immune thrombocytopenia ITP is treated by corticosteroids and/or intravenous immune globulin as the first line treatment when necessary. Mean platelet volume MPV is a marker of platelet production and function. In this study, we aimed to search the relationship between the MPV and the treatment response in ITP patients and it was hypothesized that MPV can be used as a predictor of the response. Materials and methods: The 70 newly diagnosed adult primary ITP patients and 70 of healthy people were included. MPV between ITP and healthy population, MPV in the diagnosis and after the treatment between the responders and the nonresponders were compared. Results: The responders had significantly higher MPV and the nonresponders had significantly lower MPV than the healthy population 11.09 and 10.21 fL, P = 0.03; 9.38 and 10.21 fL, P = 0.001 . MPV in the diagnosis was significantly higher in the responders than the nonresponders 11.09 and 9.38 fL, P = 0.005 . MPV significantly changed after the treatment in the responders 11.09 to 9.32 fL, P = 0.004 . Conclusion: MPV can be used as a predictor of early response to the first line treatment in newly diagnosed adult primary ITP patients.